Surufatinib Combined With Chemo Versus Surufatinib in the Treatment of Pulmonary Neuroendocrine Tumors

NCT07357623 | Recruiting Phase 2

• 1 other identifier: HMPL-012-SPRING-NEN113
• Study Type: interventional
• Target: 96
• Locations: 1 country
• Sites: 4

Brief Summary

The goal of this clinical trial is to investigate if chemotherapy works with surufatinib to treat pulmonary neuroendocrine tumors. It will also learn about the safety of this combination regimen. The main questions it aims to answer are: Does chemotherapy combined with surufatinib could bring more survival benefits (ie. higher response rate or longer survival time) for patients with pulmonary neuroendocrine tumors? Is this combination regimen safe? Researchers will compare chemotherapy plus surufatinib with surufatinib monotherapy to see if this combination regimen works to treat pulmonary neuroendocrine tumors. Participants will: Take chemotherapy(Etoposide+Carboplatin, EC or Capecitabine+Temozolomide, CAPTEM) plus surufatinib or surufatinib monotherapy every 3 or 4 weeks as a cycle. Visit the clinic once every cycle for checkups and tests. Tumor assessment is performed every 2 cycles. Treatment will continued until disease progression, death, intolerable toxicity, or withdrawn.

Conditions

Pulmonary Neuroendocrine Tumor

Keywords

surufatinib, NET, Typical carcinoid, Atypical carcinoid

Outcome Measures

Primary Outcomes (1)

• Objective response rate (ORR)(RECIST1.1)

  The incidence of confirmed complete response or partial response

  From date of enrollment to the end of treatment, an average of 1.5 years

Secondary Outcomes (4)

• Disease control rate (DCR)(RECIST1.1)

  From date of enrollment to the end of treatment, an average of 1.5 years

• Progression-free Survival (PFS) (RECIST1.1)

  From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 60 months

• Overall Survival (OS)

  From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 120 months

• 4-month PFS rate

  From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 4 months

Study Arms (2)

Surufatinib Combined With Standard chemotherapy

EXPERIMENTAL

Standard chemotherapy included either Capecitabine combined with Temozolomide or Etoposide plus Carboplatin

Drug: Surufatinib Combined With Standard chemotherapy

Surufatinib

ACTIVE COMPARATOR

Drug: Surufatinib

Interventions

Surufatinib Combined With Standard chemotherapy DRUG

Surufatinib: 250mg , qd, po, Q4W Capecitabine: 75mg/m2, bid, po, D1-D14, Q4w Temozolomide: 150mg-200mg/m2, qd, po, D10-D14, Q4W or Surufatinib: 250mg , qd, po, Q3W Etoposide: 100mg/m2, IV, D1-D3, Q3W Carboplatin: AUC=5, IV, D1, Q3W

Surufatinib Combined With Standard chemotherapy

Surufatinib DRUG

Surufatinib: 300mg, qd, po

Surufatinib

Eligibility Criteria

• Age: 18 Years - 75 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Have a full understanding of this study and voluntarily sign the informed consent form;
• years old (including cut-off value), male or female;
• Patients must have at least one measurable lesion (RECIST 1.1);
• Histologically or cytologically confirmed pulmonary neuroendocrine tumor (typical or atypical carcinoid) \[at least one neuroendocrine immunohistochemistry marker (CD56, CgA, Syn) definitively positive on the basis of morphological features of neuroendocrine tumors\];
• Patients who have not received systemic therapy in the past (Note: neoadjuvant or adjuvant chemotherapy is allowed in the early stage, and if disease progression/recurrence occurs ≥ 6 months after the end of neoadjuvant/adjuvant last therapy, it can also be included);
• ECOG PS 0-1 (PS 0-2 for amputees);
• Expected survival ≥ 12 weeks;
• Blood test (without blood transfusion within 14 days) 1) Absolute neutrophil value ≥1.5×109/L, platelet ≥ 100×109/L, hemoglobin ≥9g/dL; 2) Liver function tests (AST and ALT≤2.5×ULN, total bilirubin≤1.5×ULN; AST and ALT ≤5×ULN) if liver metastases are present; 3) Renal function (serum creatinine ≤1.5×ULN, creatinine clearance (CCr) ≥60ml/min);
• Male or female patients of childbearing potential voluntarily use effective contraceptive methods, such as double-barrier contraceptive methods, condoms, oral or injectable contraceptives, intrauterine devices, etc. during the study and within 6 months of the last study medication. All female patients will be considered of childbearing potential unless the female patient is naturally postmenopausal, has undergone artificial menopause, or has undergone sterilization (e.g., hysterectomy, bilateral adnextomy, or radioactive ovarian irradiation, etc.).

You may not qualify if:

• Patients who have received surufatinib or other anti-angiogenic drugs in the past;
• Received approved or investigational systemic anti-tumor therapy within 4 weeks before enrollment, including: chemotherapy, any form of radiotherapy, biological immunotherapy, targeted therapy, etc.;
• Participated in other domestic drug clinical trials that have not been approved or marketed within 4 weeks before enrollment and received corresponding trial drug treatment;
• Undergoing any surgery or invasive treatment or operation within 4 weeks before enrollment that affects wound healing (except for intravenous catheterization, puncture and drainage, etc.);
• International normalized ratio (INR) \> 1.5 or partially activated prothrombin time (APTT) \>1.5× ULN;
• Clinically significant electrolyte abnormalities judged by the investigator;
• Presence of hypertension that cannot be controlled by medication, as prescribed as: systolic blood pressure ≥140 mmHg and/or diastolic blood pressure ≥90 mmHg;
• Patient currently has any disease or condition that affects drug absorption, or patient cannot take surufatinib orally;
• Patients currently have active gastric and duodenal ulcers, ulcerative colitis and other gastrointestinal diseases or unresected tumors with active bleeding, or other conditions that may cause gastrointestinal bleeding and perforation as determined by the investigator;
• Patients with obvious evidence or history of bleeding tendency within 3 months prior to enrollment (bleeding \>30 mL within 3 months, hematemesis, black feces, blood in the stool), hemoptysis (\>5 mL of fresh blood within 4 weeks), or thromboembolic events (including stroke events and/or transient ischemic attack) within 12 months;
• Significant clinically significant cardiovascular disease, including but not limited to the following: acute myocardial infarction, severe/unstable angina, or coronary artery bypass grafting within 6 months before enrollment; Congestive heart failure New York Heart Association (NYHA) grade \>2; ventricular arrhythmias requiring medication; LVEF (left ventricular ejection fraction) \< 50%;
• Other malignant tumors within the past 5 years, except basal cell or squamous cell carcinoma of the skin after radical surgery, or carcinoma in situ of the cervix;
• Active or uncontrolled serious infection:
• \) Known human immunodeficiency virus (HIV) infection; 2) Known history of clinically significant liver disease, including viral hepatitis \[known hepatitis B virus (HBV) carriers must rule out active HBV infection, i.e., HBV DNA positive (\>1×104 copies/mL or \>2000 IU/ml); 3) Known hepatitis C virus infection (HCV) with positive HCV RNA (\>1×103 copies/mL), or other hepatitis, cirrhosis; 14. Known active central nervous system (CNS) metastases and/or carcinomatous meningitis. Subjects who have been previously treated for brain metastases may be enrolled provided that the patient's disease is clinically stable for at least 2 weeks and there is no evidence of new or enlarging brain metastases and steroids are off 3 days prior to administration of study drug. According to this definition, stable brain metastases should be determined prior to the first dose of study drug. Subjects with asymptomatic brain metastases (i.e., no neurological symptoms, no need for corticosteroids, and no lesions \>1.5 cm) may be enrolled, but require regular imaging of the brain as a site of disease; 15. Patients with persistent toxicity caused by any previous anti-tumor therapy that has not recovered to grade ≤2, but have any grade of alopecia and lymphopenia are allowed to participate in this study; 16. Pregnant (positive pregnancy test before medication) or breastfeeding; 17. Received blood transfusion therapy, blood products and hematopoietic factors such as albumin and granulocyte colony-stimulating factor (G-CSF) within 14 days before enrollment; 18. The investigator believes that the subject has any clinical or laboratory abnormalities or other reasons that are not suitable for participation in this clinical study; 19. Those who showed urine protein ≥ 2 and had a quantitative of \> 1.0g in 24 hours;

Sponsors & Collaborators

• Shanghai Chest Hospital: lead

Study Sites (4)

The First Affiliated Hospital Of Anhui Medical University

Hefei, Anhui, 230000, China

NOT YET RECRUITING

Peking Union Medical College Hospital

Beijing, Beijing Municipality, 100000, China

NOT YET RECRUITING

The First Affiliated Hospital of Zhengzhou University

Zhengzhou, Henan, 450000, China

NOT YET RECRUITING

Shanghai chest hospital

Shanghai, Shanghai Municipality, 200000, China

RECRUITING

MeSH Terms

Interventions

surufatinib

Central Study Contacts

Baohui Han, Phd

CONTACT

021-22200000; hanbaohui@csco.org.cn

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Chief physician

Model Details: 1:1 Randomized

Study Record Dates

• First Submitted: August 7, 2025
• First Posted: January 22, 2026
• Study Start: September 22, 2025
• Primary Completion (Estimated): September 1, 2027
• Study Completion (Estimated): September 1, 2028
• Last Updated: January 22, 2026

Record last verified: 2026-01

Data Sharing

• IPD Sharing: Will not share

Locations

CN (4)